The feasibility of developing a single agent that can deliver radioactive iodine and also direct cellular immune function by engaging endogenous antibodies, as an antibody recruiting small molecule (ARM), was determined.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
A library of new prostate-specific membrane antigen (PSMA)-binding ligands that contained antibody recruiting, 2,4-dinitrophenyl (DNP) groups and iodine, were synthesized and screened in vitro and in vivo. A lead compound (9b) showed high affinity for PSMA and the ability to bind anti-DNP antibodies. Biodistribution studies of the iodine-125 analogue showed 3% ID/g in LNCaP xenograft tumors at 1 h post-injection, with tumor-to-blood and tumor-to-muscle ratios of 10:1 and 44:1. The radiolabeled analogue was bound and internalized by LNCaP cells, with both functions blocked using a known PSMA inhibitor. A second candidate showed high tumor uptake (>10% ID/g), but had minimal binding to anti-DNP antibodies. The compounds reported represent the first examples of small molecules developed specifically for combination immunotherapy and radiotherapy for prostate cancer.
Journal of medicinal chemistry. 2016 Feb 19 [Epub ahead of print]
Afaf R Genady, Nancy Janzen, Laura Banevicius, Mahmoud El-Gamal, Mohamed E El-Zaria, John F Valliant